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AbstrACt
Objectives To investigate the accuracy, reproducibility 
and costs of different laboratory assays for the monitoring 
of unfractionated heparin (UFH) in clinical practice and to 
study test utilisation in Switzerland.
Design Prospective evaluation study and survey among 
Swiss hospitals and laboratories.
setting Secondary care hospital in rural Switzerland 
(evaluation study); all Swiss hospitals and laboratories 
(survey).
Participants All consecutive patients, monitored for 
treatment with UFH during two time periods, were included 
(May to July 2014 and January to February 2015; n=254).
Outcome measures Results of activated partial 
thromboplastin time (aPTT), thrombin time (TT), 
prothrombinase-induced clotting time (PiCT) and anti-Xa 
activity with respect to UFH concentration
results Spearman’s correlation coefficient (r
s) with regard 
to anti-Xa activity was 0.68 (95% CI 0.60 to 0.75) for 
aPTT, 0.79 (0.69 to 0.86) for TT and 0.94 (0.93 to 0.95) 
for PiCT. The correlation (r
s) between anti-Xa activity and 
heparin concentration as determined by spiking plasma 
samples was 1.0 (1.0 to 1.0). The coefficient of variation 
was at most 5% for PiCT and anti-Xa activity (within-run 
as well as day-to-day variability). The total costs per test 
in Swiss Francs (SFr) were SFr23.40 for aPTT, SFr33.30 
for TT, SFr15.70 for PiCT and SFr24.15 for anti-Xa activity. 
The various tests were employed in Swiss institutions with 
the following frequencies: aPTT 53.2%, TT 21.6%, anti-Xa 
activity 7.2%, PiCT 1.4%; 16.6% of hospitals performed 
more than one test.
Conclusions The accuracy and reproducibility of PiCT and 
anti-Xa activity for monitoring of UFH was superior, and 
analytical costs were equivalent to or lower than aPTT and 
TT.
IntrODuCtIOn 
Monitoring unfractionated heparin (UFH) 
treatment is common practice. This is mainly 
due to the experience that the patient’s 
response to UFH, measured with laboratory 
tests such as the activated partial thrombo-
plastin time (aPTT), varies greatly.1 Clinical 
data supporting laboratory monitoring of 
UFH are however scarce and the evidence is 
limited. Observational studies have suggested 
that the occurrence of thromboembolism as 
well as bleeding is associated with the heparin 
dose applied.2–5 The occurrence of thrombo-
embolism has been associated with lower aPTT 
values in small observational studies,6 7 and 
in a meta analyses of randomised controlled 
trials.8 9 Following these findings, monitoring 
of UFH is recommended by all scientific 
guidelines.1 10–12 
There is however no consensus regarding 
the optimal laboratory test to be chosen 
in clinical practice.11–13 aPTT is suggested 
most often but the application of aPTT has 
important limitations. There is significant vari-
ability in sensitivity among different reagents 
and analysers12 and the aPTT measurement 
is influenced by many factors that vary in the 
strengths and limitations of this study
 ► We studied important aspects of heparin monitoring 
comprehensively in a joint investigation and com-
pared the accuracy of activated partial thromboplas-
tin time, thrombin  time, prothrombinase-induced 
clotting time and anti-Xa measurements directly.
 ► The study was conducted in the  routine clini-
cal practice of a rural secondary care hospital in 
Switzerland.
 ► As an important limitation, our study was conducted 
in one institution only.
 ► No clinical data were recorded and conclusions 
about clinical outcomes are not possible.
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critically ill.10 The thrombin time (TT), a clotting test 
performed by adding a known concentration of bovine 
thrombin to patient plasma, is used by a number of labo-
ratories11 because TT is not influenced by factor VIII and 
other conditions associated with a prolonged baseline 
aPTT. However, the dose-response curve is not linear and 
at least two thrombin concentrations are needed to cover 
the full spectrum of drug concentration.11 14 15 Chromo-
genic anti-Xa activity assays were established16 17 but the 
reproducibility between the different assays is regarded 
as limited.18 In addition, the prothrombinase-induced 
clotting time (PiCT) assay was developed to facilitate the 
monitoring of different anticoagulants.19 The activated 
clotting time (ACT) is a rapid and easy-to-use point-of-
care test widely applied in catheterisation labs and in 
cardiac surgery.20 21 It is however influenced by many 
factors other than heparin concentration.20 21 Overall, the 
clinical and laboratory data for the above-mentioned tests 
are limited and there is still no consensus regarding the 
optimal test to be used in clinical practice.
To contribute to the discussion and help resolve the 
uncertainties associated with the various UFH tests, 
we have conducted an evaluation study to investigate 
the diagnostic accuracy, reproducibility and costs of 
the various assays in clinical practice in a primary care 
hospital in rural Switzerland. In addition, we conducted 
a survey among healthcare institutions to study utilisation 
of assays in Switzerland.
MethODs
study design, setting and population
This prospective evaluation study was conducted in a 
secondary care hospital in rural Switzerland (Spital 
Emmental, Burgdorf, Switzerland) and all tests were 
performed during routine clinical practice. All consecu-
tive patients, monitored for treatment with UFH during 
two time periods, were included (May to July 2014 and 
January to February 2015) and residual plasma samples 
were assessed with aPTT, TT, anti-Xa activity and PiCT. 
We did not apply ACT because it is used in special situ-
ations only (catheter lab, cardiac surgery) and not in a 
typical secondary care hospital. Patients were treated in 
hospital for a variety of medical and surgical diseases, and 
represent the typical mixed population of a secondary 
care hospital. The flow of the patients is shown in figure 1 
and in line with official regulations no identifying or clin-
ical data were retrieved. The laboratory of the hospital is 
accredited by the Swiss Accreditation Service.
Patient involvement
We did not involve patients at an early stage of this 
research project.
Collection and handling of blood samples
A standardised protocol for taking blood was imple-
mented at Spital Emmental to ensure direct comparisons 
and to prevent preanalytical effects.22 Plastic syringes 
containing 1 mL trisodium citrate (0.106 mol/L) per 
9 mL of blood were used (Monovette, Sarstedt, Nüm-
brecht, Germany). For practical reasons, samples were all 
frozen prior to conducting the various laboratory assays 
in the first group of patients in the study. Centrifuged 
plasma samples (1600 g for 10 min) were snap-frozen at 
−35°C, and analysed in batches. Analyses were performed 
within 4 weeks. For the second batch of patients, blood 
was taken but not frozen. The various laboratory assays 
were done within 4 hours of blood withdrawal (figure 1).
Determination of laboratory assays
aPTT was determined using HemosIL aPTT-SP (silicate 
activator; Instrumentation Laboratory, Bedford, Massa-
chusetts, USA). Fifty microlitres of patient plasma were 
mixed with 50 µl of aPTT-SP. TT is a coagulation test 
measuring the time to fibrin formation after adding 
thrombin.23 Because of a high sensitivity for heparin, two 
thrombin concentrations are necessary to cover the full 
spectrum of heparin concentration. We used 3 U/mL (TT 
1) and 7.5 U/mL (TT 2) of bovine thrombin (HemosIL 
TT; Instrumentation Laboratory, Bedford, Massachusetts, 
USA). TT 2 was determined in case of an unclottable 
TT 1 corresponding to a high concentration of heparin. 
Anti-Xa activity was determined using HemosIL liquid 
anti-Xa (Instrumentation Laboratory, Bedford, Massachu-
setts, USA), calibrated with HemosIL heparin calibrators. 
PiCT was measured using Pefakit PiCT (DSM Penta-
pharm, Basel, Switzerland). The test has been described 
in detail elsewhere.19 24 Briefly, 50 µL of patient plasma 
was incubated for 180 s with an activator containing acti-
vated factor Xa, phospholipids and Russell’s viper venom. 
Coagulation was initiated with calcium chloride and clot-
ting time (s) measured. All analyses were performed on 
an ACL TOP 300 (Instrumentation Laboratory, Bedford, 
Massachusetts, USA).
Determination of the anti-Xa calibration curve
Scientific guidelines recommend calibration of labora-
tory tests used for heparin monitoring against plasma 
heparin concentration using methods such as anti-Xa 
activity or protamine titration.13 25 26 Whereas the accu-
racy of aPTT, TT and PiCT was investigated in relation 
to the anti-Xa activity, we demonstrated the accuracy 
of the anti-Xa activity assay with regard to the heparin 
concentration as determined using a titration study. A 
plasma pool was generated by mixing 5 mL of citrated 
plasma from 20 healthy volunteers demonstrated to 
have aPTT, PT, TT and fibrinogen concentrations within 
the reference range. A stock solution was prepared by 
adding 0.1 mL of UFH (HEPARIN Fresenius, 5,000 IU/
mL, Fresenius Medical Care, Oberdorf, Switzerland) to 
9.9 mL of plasma pool, resulting in a concentration of 50 
IU/mL. This stock solution was diluted by 1:100 to obtain 
a working solution of 0.5 IE/mL. Decreasing volumes of 
the working solutions were added to increasing volumes 
of the plasma pool, resulting in samples with a heparin 
concentration ranging between 0.00 IU/ mL and 1.0 IU/
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mL. Anti-Xa activity was determined and a calibration 
curve created.
reproducibility
We investigated the reproducibility of the above-men-
tioned laboratory assays by repeating the measurements 
one after another in one run using two samples, one 
with normal results and one with abnormal results (with-
in-run variability). The day-to-day variability was studied 
by repeating the measurements using frozen aliquots of 
two samples (abnormal and normal, respectively).
Costs
We calculated the analytical cost of the various assays by 
taking the following factors into consideration: reagents, 
controls, calibrators, consumables and time taken. 
Labour costs were estimated according to the average 
wage of a qualified technician in Switzerland (SFr42, per 
hour). We considered the determination of TT 2 in 48% 
of cases (as done in our investigation) corresponding to a 
high concentration of heparin. For the determination of 
the time taken, we included the centrifugation time, time 
for analysis, as well as validation. Costs were based on the 
Swiss healthcare system.
Monitoring of uFh in clinical practice—a survey among swiss 
healthcare institutions
Two sources were used to identify the Swiss healthcare 
institutions, which monitor UFH. First, the official list 
of hospitals, published by the Federal Office of Public 
Health (Federal Office of Public Health, Key figures 
for Swiss hospitals (Internet). 2013 (cited 01 November 
2016). Available from: https://www. bag. admin. ch/ bag/ 
en/ home/ service/ zahlen- fakten/ zahlen- fakten- zu- spit-
aelern/ kennzahlen- der- schweizer- spitaeler. html), and 
second, a list of laboratories providing training for labo-
ratory specialists, issued by the Swiss Society of Medical 
Laboratories (FAMH) (The medical laboratories of 
Switzerland (FAMH), FAMH Weiterbildungsstätten 
(Internet). 2016 (cited 01 November 2016). Available 
from: https://www. famh. ch/ weiterbildung- fortbildung/ 
weiterbildung/ famh- weit erbi ldun gsst aetten/). The 
downloaded information was checked and duplicate 
Figure 1 Flow of the samples. aPTT, activated partial thromboplastin time; PiCT, prothrombinase-induced clotting time; 
UFH, unfractionated heparin.
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entries were removed. A structured telephone interview 
was then conducted with the senior technician at each 
laboratory and the details recorded regarding the labora-
tory tests used to monitor UFH.
statistical analysis
Numbers and percentages were reported as appropriate. 
We calculated the Spearman correlation coefficients to 
describe associations between results of aPTT, TT, PiCT, 
anti-Xa activity and heparin concentration. A linear 
regression according to the Deming procedure was addi-
tionally calculated. The coefficient of variation (CV) was 
used to describe within-run as well as day-to-day variability 
(mean is reported). No explicit power calculation has 
been done. Analyses were performed using the Stata 
V.14 statistics software package (Stata Statistical Software: 
Release 14; StataCorp, 2014; College Station, Texas, USA); 
figures were created using Prism V.6 (GraphPad Software, 
La Jolla California USA).
results
Patient samples
Samples from 254 patients receiving treatment with UFH 
between May 2014 and February 2015 were evaluated. 
The flow of the samples is shown in figure 1. Between 
May to July 2014, blood samples were snap-frozen and 
analysed in batches; between January to February 2015, 
samples were analysed within 4 hours following the taking 
of blood.
Accuracy
The correlation between the different laboratory assays 
and anti-Xa activity is shown in table 1 which shows the 
values associated with all samples as well as the outcomes 
for the frozen or unfrozen batches. Figure 2 illustrates 
the distribution of the results and shows the regression 
line according to the Deming procedure. In relation to 
anti-Xa activity, the overall Spearman correlation coeffi-
cient (rs) was 0.68 (95% CI 0.60 to 0.75) for aPTT, 0.79 
(0.69 to 0.86) for TT and 0.94 (0.93 to 0.95) for PiCT. 
Even though differences were noted between the frozen 
and unfrozen samples, the overall findings remain 
the same. Correlation (rs) between anti-Xa activity 
and heparin concentration was 1.0 (95% CI 1.0 to 1.0; 
figure 3).
reproducibility
Measures of reproducibility are reported in table 2. 
Within-run variability, as determined by CV, was 5.7% for 
aPTT, 14.7% for TT (high concentration), 2.5% for PiCT 
and 3.4% for anti-Xa. Day-to-day variability was 3.7% 
for aPTT, 6.1% for TT, 1.1 for PiCT and 5.0 for anti-Xa 
activity.
Table 1 Accuracy of the various laboratory tests for heparin monitoring in clinical practice
Assay Observations
Spearman’s correlation coefficient (95% CI)
Regression 
coefficients*
All samples Unfrozen only Frozen only
aPTT† 193 0.68 (0.60 to 0.75) 0.62 (0.36 to 0.79) 0.71 (0.63 to 0.78) Y=158.6*X+22.3
TT 1 (low)† 163 0.73 (0.65 to 0.79) 0.79 (0.66 to 0.87) 0.71 (0.60 to 0.79) Y=173.7*X+1.86
TT 2 (high)† 87 0.79 (0.69 to 0.86) 0.72 (0.54 to 0.84) 0.85 (0.74 to 0.92) Y=94.0*X–24.2
PiCT† 254 0.94 (0.93 to 0.95) 0.96 (0.94 to 0.97) 0.93 (0.91 to 0.95) Y=189.5*X+24.6
Anti-Xa‡ 14 1.0 (95% CI 1.0 to 1.0) N/A N/A Y=1.005*X+0.03977
*Linear regression according to the Deming procedure was used.
†With regard to anti-Xa activity.
‡With regard to a calibration curve derived from dilution studies using heparin-spiked plasma samples.
aPTT, activated partial thromboplastin time; PiCT, prothrombinase-induced clotting time; TT 1, thrombin time 1 (3 U/mL bovine thrombin), TT 
2, thrombin time 2 (7.5 U/mL bovine thrombin).
Figure 2 Accuracy of different assays for heparin monitoring in clinical practice. (A) Activated partial thromboplastin time 
(aPTT), (B) thrombin time (high concentration), (C) prothrombinase-induced clotting time (PiCT). Scattergram with regression 
curves (Deming procedure) and correlation coefficients are shown.
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time and cost estimates
The overall costs for each of the assays in Swiss Francs 
(SFr) were found to be SFr23.40 (aPTT), SFr33.30 (TT), 
SFr15.70 (PiCT) and SFr24.15 (anti-Xa activity). The 
times and costs required for each assay type were calcu-
lated are reported in table 3 with PiCT costing the least.
Monitoring of uFh in switzerland
One hundred and thirty-nine Swiss institutions were iden-
tified which conduct heparin monitoring in clinical prac-
tice. The vast majority of institutions implemented aPTT, 
TT or both assays (84.9%). Of the institutions 53.2 % 
relied exclusively on aPTT, 13.7% on anti-Xa activity and 
PiCT was used by just two institutions (1.4%). Further 
details are provided in table 4.
DIsCussIOn
We found that concordance of laboratory measurements 
with heparin concentration was better for anti-Xa activity 
and PiCT compared with aPTT and TT. Reproducibility 
of anti-Xa and PiCT was at least comparable to aPTT. 
Analytical costs of PiCT were lower compared with aPTT. 
The majority of Swiss institutions conduct aPTT or TT for 
heparin monitoring.
Concordance of aPTT with heparin concentration is 
generally regarded as poor.26–28 The correlation coef-
ficients we found are in line with previous studies. 
Bounameaux et al,14 in a study of 63 plasma samples, 
determined that Pearson’s correlation coefficient was 
0.85 in case of TT and 0.67 in case of aPTT. In another 
analysis of 49 patients,15 a coefficient of determination 
(r2) of 0.63 for aPTT and 0.74 for TT was found. A multi-
centre study in 377 patients returned a correlation of 0.76 
for aPTT with anti-Xa levels.24 A limited agreement has 
been observed in a prospective study in 569 patients.29 
Several studies have demonstrated a dose-dependent 
prolongation of TT.12 14 15 In agreement with our results, 
alignment with heparin concentration was better with 
aPTT. Correlation of PiCT with anti-Xa levels was r=0.88 
in a multicentre study in 377 patients.24 With regard to 
the anti-Xa activity, one small randomised controlled trial 
compared anti-Xa activity assay monitoring with aPTT 
and reported fewer complications in the case of anti-Xa.30
The strength of our investigation is that we have studied 
several important aspects of heparin monitoring in clin-
ical practice in Switzerland in a joint investigation and 
compared the accuracy of aPTT, TT, PiCT and anti-Xa 
measurements directly.
Our study was conducted in one institution only. There-
fore, we cannot exclude that results could be different 
if analyses were conducted in other laboratories. This 
Figure 3 Anti-Xa calibration curve according to titration 
studies using unfractionated heparin.
Table 2 Reproducibility of different laboratory tests for heparin monitoring in clinical practice
Assay
Within-run variability
Number of 
measurements Day-to-day variability Number of 
measurementsCV CV
aPTT 5.7% 10 3.7% 15
TT 2 (low) 14.7% 10 6.1% 15
PiCT 2.5% 10 1.1% 15
Anti-Xa 3.4% 10 5.0% 15
aPTT, activated partial thromboplastin time; CV, coefficient of variation (%); PiCT, prothrombinase-induced clotting time; TT 2, thrombin time 2 
(7.5 U/mL bovine thrombin).
Table 3 Laboratory tests for heparin monitoring in clinical 
practice: time and cost
Test
Time required for 
measurement* (min)
Cost of the 
analysis† (in SFr)
aPTT 21 23.40
TT 28‡ 33.30‡
PiCT 20 15.70
Anti-Xa 17 24.15
*Including centrifugation, analysis and validation.
†Including reagents, calibrators, quality control as well as work 
expended; labour costs were estimated according to the average 
wage of a qualified technician in Switzerland (SFr42 per hour).
‡Determination of thrombin time 2 (high concentration) in 48% of 
the cases was considered.
aPTT, activated partial thromboplastin time; PiCT, prothrombinase-
induced clotting time; TT, thrombin time.
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issue should be studied in future investigations. Second, 
samples were treated differently between the two phases 
of our study; the first batch of samples were frozen prior 
to conducting the laboratory assays for practical reasons, 
and the second batch were not frozen. Although the 
results between these two batches of samples were found 
to differ (table 1), the differences found between the 
various assays nevertheless remained the same. And 
thirdly, correlation coefficient is not an ideal accuracy 
measure in case of TT, because correlation with heparin is 
not linear and two concentrations are needed to monitor 
UFH. Finally, there were no clinical data retrieved. There-
fore, conclusions about clinical outcomes are not possible.
In conclusion, we have found that performance of 
PiCT and anti-Xa activity for heparin monitoring is supe-
rior to TT and aPTT in a single centre evaluation study in 
a secondary care hospital in Switzerland.
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